Patent intelligence · EP
EP 2819679
FLÜSSIGE FORMULIERUNGEN ENTHALTEND HYPOGLYZEMISCHE SULFAMIDE
FLÜSSIGE FORMULIERUNGEN ENTHALTEND HYPOGLYZEMISCHE SULFAMIDE
Patent details — EP 2819679
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Jan 7, 2015
- Expiration
- Jan 2, 2035
- Applicant
- AMMTEK [FR]
- CPC classes
- A61K 9/ 10 A I, A61K 31/ 64 A I, A61K 47/ 36 A I, A61K 47/ 38 A I
Quick answer
EP 2819679 (FLÜSSIGE FORMULIERUNGEN ENTHALTEND HYPOGLYZEMISCHE SULFAMIDE) is held by AMMTEK [FR]. Status: granted. Granted Jan 7, 2015. Expires Jan 2, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AMMTEK [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 10 A I, A61K 31/ 64 A I, A61K 47/ 36 A I, A61K 47/ 38 A I, A61K/3164, A61K/4738
Frequently asked questions
What is US patent 2819679?
EP 2819679 (FLÜSSIGE FORMULIERUNGEN ENTHALTEND HYPOGLYZEMISCHE SULFAMIDE) is held by AMMTEK [FR]. Status: granted. Granted Jan 7, 2015. Expires Jan 2, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 2819679?
AMMTEK [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does EP 2819679 expire?
Our index shows an expiration date of Jan 2, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.